Thirdly, the possible targets identified in this study, ERβ and Her2, belong to the luminal marker panel, which is downregulated in the process of invasion, possibly limiting the suitability of ERβ and Her2 targeting to CIS and should encourage combined therapy modalities. Here, ESR2 is linked to in situ carcinoma.